[Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists].
sheinzl@wissenschaftlicheverlgsgesellschaft.de
Susanne
S
Heinzl
D000218:Adamantane / Q000031:analogs & derivatives / Q000627:therapeutic use; D058892:Adenosine Deaminase Inhibitors; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D018819:Dipeptidyl Peptidase 4; D005998:Glycine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006023:Glycoproteins / Q000037:antagonists & inhibitors*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D009570:Nitriles; D010080:Oxazoles / Q000627:therapeutic use; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists*; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use; D011759:Pyrrolidines; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000627:therapeutic use; D000077597:Vildagliptin
D058892:Adenosine Deaminase Inhibitors; D006023:Glycoproteins; D007004:Hypoglycemic Agents; D009570:Nitriles; D010080:Oxazoles; D047492:Peroxisome Proliferator-Activated Receptors; D011480:Protease Inhibitors; D011719:Pyrazines; D011759:Pyrrolidines; D014230:Triazoles; C042807:DPP4 protein, human; D018819:Dipeptidyl Peptidase 4; D000077597:Vildagliptin; D000218:Adamantane; D005998:Glycine; D000068900:Sitagliptin Phosphate; C500085:muraglitazar